Gamma-Aminobutyric Acid Binding to Receptor Sites in the Rat Central Nervous System (Neurotransmitter/Bicuculline/Synaptic Membranes/Glycine/Strychnine) STEPHEN R

Total Page:16

File Type:pdf, Size:1020Kb

Gamma-Aminobutyric Acid Binding to Receptor Sites in the Rat Central Nervous System (Neurotransmitter/Bicuculline/Synaptic Membranes/Glycine/Strychnine) STEPHEN R Proc. Nat. Acad. Sci. USA Vol. 71, No. 12, pp. 4802-4807, December 1974 Gamma-Aminobutyric Acid Binding to Receptor Sites in the Rat Central Nervous System (neurotransmitter/bicuculline/synaptic membranes/glycine/strychnine) STEPHEN R. ZUKIN, ANNE B. YOUNG, AND SOLOMON H. SNYDER* Departments of Pharmacology and Experimental Therapeutics, and Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 Communicated by David Bodian, September 16, 1974 ABSTRACT 18H]Gamma-aminobutyric acid (GABA) brains were rapidly removed and homogenized in 15 volumes binds to synaptic membrane fractions of rat brain in a M sucrose in a Potter-Elvehjem glass homog- selective fashion representing an interaction with post- of ice-cold 0.32 synaptic GABA receptors. Inhibition of ['H1GABA bind- enizer fitted with a Teflon®D pestle. The homogenate was ing by a variety of amino acids closely parallels their ability centrifuged at 1000 X g for 10 min, the pellet was discarded, to mimic the synaptic inhibitory actions of GABA and and the supernatant fluid was centrifuged at 20,000 X g for 20 does not correlate with their relative affinity for the pre- min. The crude mitochondrial pellet was resuspended in synaptic synaptosomal GABA uptake system. ['HIGABA binding is saturable with an affinity constant of about 0.1 distilled water and dispersed with a Brinkmann Polytron MM. The GABA antagonist bicuculline inhibits ['HIGABA PT-10 sonicator (setting 6) for 30 sec. The suspension was binding with half maximal effects at 5 MM, whereas it re- centrifuged at 8000 X g for 20 min. The supernatant was col- quires a concentration of 0.5 mM to reduce synaptosomal lected and the pellet, a bilayer with a soft, buffy uppercoat, GABA uptake by 50%. In subcellular fractionation experi- was rinsed carefully with the supernatant fluid to collect the ments ['H]GABA binding is most enriched in crude synap- tic membranes. [8IH]GABA binding is greatest in the cere- upper layer. The combined supernatant fraction was then bellum, least in the spinal cord and medulla oblongata- centrifuged at 48,000 X g for 20 min. The final crude synaptic pons, with intermediate values in the thalamus, hippo- membrane pellets were resuspended in H20 and centrifuged campus, hypothalamus, cerebral cortex, midbrain, and at 48,000 X g for 20 min and then stored at -30° for at least corpus striatum. 18 hr. The frozen pellets were resuspended in H20, maintained Gamma-aminobutyric acid (GABA) is a major inhibitory at 250 for 20 min, centrifuged at 48,000 X g for 10 min and the neurotransmitter in the mammalian central nervous system pellets were then suspended in the buffer for GABA binding (1-4). Its inhibitory actions are selectively antagonized by the assay. ['H]GABA binding capacity remained intact for at alkaloid bicuculline, in contrast to the inhibitory actions of least 30 days under these conditions. Storing frozen tissue glycine, which are selectively antagonized by strychnine enhances GABA receptor binding and markedly lowers (5-8). The synaptic activities of GABA may be terminated sodium-dependent GABA binding unrelated to receptor sitest. by a high-affinity, sodium-requiring uptake system into GABA Binding Assay. Aliquots of crude synaptic membranes nerve terminals (9, 10) and possibly glia (11-13). The sodium- (0.3-1.2 mg of protein) were incubated in triplicate at 40 for 5 dependent binding of GABA to membrane preparations of min in 2 ml of 0.05 M Tris-citric acid buffer (pH 7.1 at 40) mammalian brain largely represents binding of GABA to containing approximately 32 nM ['H]-y-aminobutyric acid uptake sites, since the relative affinity of a variety of amino (GABA) (500,000 cpm) alone or in the presence of 1 mM acids and drugs in preventing this binding parallels their GABA, 0.1 mM bicuculline, or other indicated drugs. Time affinity for the GABA uptake system but differs markedly course experiments indicated that specific [3H]GABA binding from their relative abilities to mimic the synaptic inhibitory is at equilibrium within 5 min under these conditions. After actions of GABA (6, 14, 15,t). incubation, the reaction was terminated by centrifugation for Here we report binding of [8H]GABA to crude synaptic 10 min at 48,000 X 9. The supernatant fluid was decanted, membrane fractions of the rat central nervous system which and the pellet was rinsed rapidly and superficially with 5 ml, appears to represent a specific interaction with the post- then 10 ml of ice-cold distilled H20. Bound radioactivity was synaptic GABA receptor. extracted into 1 ml of Protosol (New England Nuclear Corp.), 10 ml of toluene phosphor were added, and radioactivity was MATERIALS AND METHODS assayed by liquid scintillation spectrometry (Packard Tricarb Tissue Preparation. Subcellular fractionation utilized a model 3385 or 3375), at a counting efficiency of 34%. Analysis modification of previously described techniques (16-20). Male of the membrane-bound radioactivity by thin layer chroma- Sprague-Dawley rats (100-200 g) were decapitated and the tography in three solvent systems indicated that all of the bound material was authentic GABA. Specific [8H]GABA binding was obtained by subtracting Abbreviation: GABA, gamma-aminobutyric acid. from the total bound radioactivity the amount not displaced * To whom reprint requests should be sent at the Department of by high concentrations of bicuculline (0.1 mM) or GABA (1 Pharmacology. mM). Except when otherwise indicated, values for nonspecific t S. Enna and S. H. Snyder, in preparation. binding were the same whether bicuculline or GABA was used 4802 Downloaded by guest on September 29, 2021 Proc. Nat. Acad. Sci. USA 71 (1974) Gamma-Aminobutyric Acid Receptor 4803 TABLE 1. Subcellular distribution of specific [8H]GABA binding in the rat brain Specific [3H]GABA binding Specific: O 2000 Binding Total binding nonspecific z a (cpm/mg per fraction binding z Fraction of protein) (cpm) ratio m 1600 - Whole homogenate 282 12,708 0.11 Crude nuclear G 1200 - pellet (Pi) 209 2100 0.10 Crude mitochondrial 800 0.44 pellet (P2) 1068 14,858 a. Crude microsomal CD 400 pellet (P8) 0 0 Osmotically shocked P2 subfractions 0 1.0 2.0 3.0 4.0. Mitochondria-myelin mg of MEMBRANE PROTEIN/2ml pellet 210 1829 0.11 FIG. 1. Effect of synaptic membrane concentration on specific Crude synaptic [3HJGABA binding. Various amounts of synaptic membrane membrane pellet 1517 18,177 0.66 suspensions obtained from rat brain were incubated for 5 min at 40 with 34 nM [3HJGABA (500,000 cpm) alone or in the presence Tissues were prepared and subjected to differential centrifuga- of 0.1 mM bicuculline in a total volume of 2 ml. Each point is the tion as described in the text. The crude microsomal pellet was ob- mean of triplicate determinations which varied <10%. The ex- tained by centrifugation of the supernatant fluid remaining after periment has been replicated twice. centrifugation of the crude mitochondrial pellet at 100,000 X g for 1 hr. The various pellets were resuspended in 50 mM Tris-citric pellet probably does not contain large amounts of GABA acid buffer (pH 7.1) (0.7-1.2 mg of membrane protein per 2 ml) binding activity. and assayed as described. The experiment has been replicated When the P2 pellet is subjected to hypotonic shock, nerve twice. endings are lysed and subsequent differential centrifugation can resolve a low-speed pellet containing mitochondria and as a displacer. Protein was measured by the method of Lowry myelin from a high-speed fraction which is enriched in et al. (21). synaptic membranes (16). The crude synaptic membrane fraction contains about 10 times as much GABA binding as Uptake Studies. Uptake of radioactive GABA was assayed the mitochondria-myelin pellet and has a specific activity as previously described (22-25). more than five times that of the original homogenate. The Materials. [3H]GABA (specific activity 10 Ci/mmol) was crude synaptic membrane fraction has been used for routine obtained from New Nuclear GABA binding assays. Specific binding of [3H]G-ABA to England Corp. Picrotoxin, and 2 of whole purchased from Sigma Chemical Corp., and bicuculline, from synaptic membranes is linear between 0.5 mg Pierce Chemical Co., were dissolved immediately prior to use brain membrane protein (Fig. 1). Binding studies are routinely because of their chemical lability. performed within this linear range. During preparation of the crude synaptic membrane frac- RESULTS tion from brain homogenates, the ratio of specific to non- Subeellular localization of [3H]GABA binding specific GABA binding increases progressively. Thus in the in the rat brain whole homogenate specific GABA binding is only 10% of the total. The ratio of specific to nonspecific binding in the crude The distribution of specific [3HIGABA binding in subcellular mitochondrial is four times that of the whole fractions of whole rat brain was measured in fractions prepared pellet homog- enate, while the crude synaptic membrane fraction displays a by a modification of previously described techniques (16-20) six of whole Thus in routine (Table 1). Among the primary fractions obtained by differen- ratio times that the homogenate. assays with the synaptic membrane fraction, about tial the largest amount of binding is recovered 40-50% centrifugation, of [3H]GABA binding is displaced by 0.1 mM bicuculline or 1 in the crude mitochondrial pellet (P2) which contains both mM GABA. pinched-off nerve endings ("synaptosomes") and free mito- chondria. Total specific binding in the P2 pellet is as great or Saturability of I3HJGABA binding to synaptic membranes greater than that of the whole homogenate, while binding in of whole rat brain the crude nuclear pellet is only about 1/6th that of the whole Specific [3H]GABA binding is saturable with increasing con- homogenate, and no specific binding can be detected in the centration, with half-maximal binding occurring at approxi- crude microsomal pellet.
Recommended publications
  • (12) United States Patent (10) Patent No.: US 8,822,539 B2 Jensen (45) Date of Patent: Sep
    USOO8822.539B2 (12) United States Patent (10) Patent No.: US 8,822,539 B2 Jensen (45) Date of Patent: Sep. 2, 2014 (54) COMBINATION THERAPIES: INHIBITORS Bialer et al., “Progress report on new antiepileptic drugs: a Summary OF GABA TRANSAMINASE AND NKCC1 of the Seventh Eilat Conference (EILATVII).” Epilepsy Res., 61:1- 48, 2004 (Abstract only). (75) Inventor: Frances E. Jensen, Boston, MA (US) Clift and Silverman, “Synthesis and Evaluation of Novel Aromatic Substrates and Competitive Inhibitors of GABA Aminotransferase.” (73) Assignee: Children's Medical Center Bioorg. Med. Chem. Left., 18:3122-3125, 2008. Crewther et al., “Potassium Channel and NKCC Cotransporter Corporation, Boston, MA (US) Involvement in Ocular Refractive Control Mechanisms. PlosOne, 3:e2839, 2008. (*) Notice: Subject to any disclaimer, the term of this Cubells et al., “In vivo action of enzyme-activated irreversible inhibi patent is extended or adjusted under 35 tors of glutamic acid decarboxylase and gamma-aminobutyric acid U.S.C. 154(b) by 149 days. transaminase in retina vs. brain.” J. Pharmacol. Exp. Ther. 238:508 514, 1986 (Abstract only). (21) Appl. No.: 13/069,311 Duboc et al., “Vigabatrin, the GABA-transaminase inhibitor, dam ages cone photoreceptors in rats.” Ann. Neurol. 55:695-705, 2004 (22) Filed: Mar 22, 2011 (Abstract only). Dzhala et al., “Bumetanide enhances phenobarbital efficacy in a (65) Prior Publication Data neonatal seizure model.” Ann. Neurol. 63:222-235, 2008 (Abstract US 2011/0237554 A1 Sep. 29, 2011 only). Dzhala et al., “NKCC1 transporter facilitates seizures in the devel oping brain.” Nature Med., 11:1205-1213, 2005 (Abstract only). Follett et al., “Glutamate Receptor-Mediated Oligodendrocyte Tox Related U.S.
    [Show full text]
  • The Syntheses of Β-Lactam Antibiotics from 3-Formylcephalosporins As the Key-Intermediates
    PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/19082 Please be advised that this information was generated on 2021-10-03 and may be subject to change. The Syntheses of β-Lactam Antibiotics from 3-Formylcephalosporins as the Key-intermediates Een wetenschappelijke proeve op het gebied van de Natuurwetenschappen, Wiskunde en Informatica Proefschrift ter verkrijging van de graad van doctor aan de Katholieke Universiteit Nijmegen, volgens besluit van het College van Decanen in het openbaar te verdedigen op woensdag 6 februari 2002 des namiddags om 1.30 uur precies door Rolf Keltjens Geboren op 9 april 1972 te Horst Promotor Prof. dr. B. Zwanenburg Copromotor Dr. A.J.H. Klunder Manuscriptcommissie Dr. E. de Vroom (DSM Anti-Infectives, Delft) Dr. J. Verweij (voorheen DSM Anti-Infectives, Delft) Prof. dr. ir. J.C.M. van Hest The research described in this PhD thesis was part of the Cluster Project "Fine- Chemistry" and was financially supported by DSM (Geleen, The Netherlands) and the Dutch Ministry of Economical Affairs (Senter). ISBN 90-9015389-6 Omslag: Penicillium chrysogenum (copyright DSM N.V.) "Experiment is the sole interpreter of the artifices of Nature" Leonardo da Vinci (1452-1519) Aan mijn ouders Paranimfen René Gieling Sander Hornes VOORWOORD Als het manuscript nagenoeg gereed is en het geheel klaar is voor verzending naar de drukker, is het ook de hoogste tijd om de mensen met wie je vier jaar lang intensief hebt samengewerkt te bedanken.
    [Show full text]
  • 1 Abietic Acid R Abrasive Silica for Polishing DR Acenaphthene M (LC
    1 abietic acid R abrasive silica for polishing DR acenaphthene M (LC) acenaphthene quinone R acenaphthylene R acetal (see 1,1-diethoxyethane) acetaldehyde M (FC) acetaldehyde-d (CH3CDO) R acetaldehyde dimethyl acetal CH acetaldoxime R acetamide M (LC) acetamidinium chloride R acetamidoacrylic acid 2- NB acetamidobenzaldehyde p- R acetamidobenzenesulfonyl chloride 4- R acetamidodeoxythioglucopyranose triacetate 2- -2- -1- -β-D- 3,4,6- AB acetamidomethylthiazole 2- -4- PB acetanilide M (LC) acetazolamide R acetdimethylamide see dimethylacetamide, N,N- acethydrazide R acetic acid M (solv) acetic anhydride M (FC) acetmethylamide see methylacetamide, N- acetoacetamide R acetoacetanilide R acetoacetic acid, lithium salt R acetobromoglucose -α-D- NB acetohydroxamic acid R acetoin R acetol (hydroxyacetone) R acetonaphthalide (α)R acetone M (solv) acetone ,A.R. M (solv) acetone-d6 RM acetone cyanohydrin R acetonedicarboxylic acid ,dimethyl ester R acetonedicarboxylic acid -1,3- R acetone dimethyl acetal see dimethoxypropane 2,2- acetonitrile M (solv) acetonitrile-d3 RM acetonylacetone see hexanedione 2,5- acetonylbenzylhydroxycoumarin (3-(α- -4- R acetophenone M (LC) acetophenone oxime R acetophenone trimethylsilyl enol ether see phenyltrimethylsilyl... acetoxyacetone (oxopropyl acetate 2-) R acetoxybenzoic acid 4- DS acetoxynaphthoic acid 6- -2- R 2 acetylacetaldehyde dimethylacetal R acetylacetone (pentanedione -2,4-) M (C) acetylbenzonitrile p- R acetylbiphenyl 4- see phenylacetophenone, p- acetyl bromide M (FC) acetylbromothiophene 2- -5-
    [Show full text]
  • Light and Electron Microscope Evidence for Involvement of Neuroglia (Cerebellum/Cyclic AMP/Y-Aminobutyric Acid/Harmaline/Diazepam) V
    Proc. Natl. Acad. Sci. USA Vol. 76, No. 3, pp, 1485-1488, March 1979 Neurobiology Immunocytochemical localization of cyclic GMP: Light and electron microscope evidence for involvement of neuroglia (cerebellum/cyclic AMP/y-aminobutyric acid/harmaline/diazepam) V. CHAN-PALAY* AND S. L. PALAYt Departments of *Neurobiology and tAnatomy, Harvard Medical School, Boston, Massachusetts 02115 Contributed by Sanford L. Palay, December 7, 1978 ABSTRACT Guanosine 3',5'-cyclic monophosphate (cGMP) presents cytopharmacological evidence from immunocyto- immunoreactivity in the rat's cerebellum was studied with light chemistry for the cellular and subcellular location of cGMP in and electron microscopy by the indirect fluorescence method some cerebellar neurons and particularly in neuroglial cells. and the peroxidase-antiperoxidase method. Labeled cells in- cluded neuroglial cells in the cerebellar cortex, white matter, and deep nuclei; some stellate and basket cells in the cortex; and MATERIALS AND METHODS some large neurons in the deep nuclei. No evidence was found Adult 200-300 g Sprague-Dawley rats, the indirect immu- for sagittal microzonation in the cGMP distribution. In the la- nofluorescence method (11), and the peroxidase-antiperoxidase beled cells, cGMP immunoreactive sites were localized to sur- face membranes, organelles, and the cytoplasmic matrix. (PAP) method (12) for light and electron microscopy were used. Specificity was indicated by the same pattern of labeling after Rabbit antisera were raised against the 2'-O-succinyl derivative treatment with cGMP immunoglobulin that had been adsorbed of cGMP or cAMP conjugated to limpet hemocyanin (13). More with adenosine 3',5'-cyclic monophosphate (cAMP) and by the than 50% of 2'-O-succinyl-cGMP ([125I]iodotyrosine methyl failure to label after treatment with normal rabbit sera or with ester derivative) or 2'-O-succinyl-cAMP ([1251]iodotyrosine cGMP immunoglobulin that had been adsorbed with 1 mM methyl ester derivative) (<0.01 pmol) was bound at a serum cGMP.
    [Show full text]
  • Increase in the Bmax of Y-Aminobutyric Acid-A Recognition Sites in Brain Regions of Mice Receiving Diazepam
    Proc. Nati. Acad. Sci. USA Vol. 81, pp. 2247-2251, April 1984 Neurobiology Increase in the Bmax of y-aminobutyric acid-A recognition sites in brain regions of mice receiving diazepam (muscimol/-aminobutyric acid receptors/benzodiazepine receptors/locomotor activity) P. FERRERO, A. GuIDOTTI, AND E. COSTA* Laboratory of Preclinical Pharmacology, National Institute of Mental Health, Saint Elizabeths Hospital, Washington, DC 20032 Contributed by E. Costa, December 12, 1983 ABSTRACT y-Aminobutyric acid (GABA) receptors were MATERIALS AND METHODS characterized in vivo by studying ex vivo the binding of [3H]Muscimol (New England Nuclear) labeled on the meth- [3H]muscimol to cerebellum, cortex, hippocampus, and cor- ylene side-chain (specific activity, 29.4 Ci/mmol; 1 Ci = 37 pus striatum of mice receiving intravenous injections of tracer GBq) was injected into the tail vein of female mice (20-25 g). doses of high-specific-activity (-30 Ci/mmol) [3H]muscimol. Routinely, the dose of [3H]muscimol injected was 5 uCi per This ligand binds with high affinity (apparent Kd, 2-3 x 10-9 20 g of body weight in 0.2 ml of saline. This radiolabeled M) to a single population of binding sites (apparent Bmax, 250- ligand dose was administered either alone or with various 180 fmol per 10 mg of protein). Pharmacological studies using doses of unlabeled muscimol. In some experiments, drugs that selectively bind to GABAA or GABAB receptors [3H]muscimol was injected into cerebral ventricles through a suggest that [3H]muscimol specifically labels a GABAA recog- polyethylene cannula chronically implanted (13). The dissec- nition site. Moreover, diazepam (1.5 ,umol/kg, i.p.) increases tion of the different brain areas (cerebellum, cortex, stria- the Bmax but fails to change the affinity of [3Hlmuscimol bind- tum, and hippocampus) was carried out on a chilled (00C) ing to different brain areas.
    [Show full text]
  • Pharmacological Studies on a Locust Neuromuscular Preparation
    J. Exp. Biol. (1974). 6i, 421-442 421 *&ith 2 figures in Great Britain PHARMACOLOGICAL STUDIES ON A LOCUST NEUROMUSCULAR PREPARATION BY A. N. CLEMENTS AND T. E. MAY Woodstock Research Centre, Shell Research Limited, Sittingbourne, Kent {Received 13 March 1974) SUMMARY 1. The structure-activity relationships of agonists of the locust excitatory neuromuscular synapse have been reinvestigated, paying particular attention to the purity of compounds, and to the characteristics and repeatability of the muscle response. The concentrations of compounds required to stimu- late contractions of the retractor unguis muscle equal in force to the neurally evoked contractions provided a measure of the relative potencies. 2. Seven amino acids were capable of stimulating twitch contractions, glutamic acid being the most active, the others being analogues or derivatives of glutamic or aspartic acid. Aspartic acid itself had no excitatory activity. 3. Excitatory activity requires possession of two acidic groups, separated by two or three carbon atoms, and an amino group a to a carboxyl. An L-configuration appears essential. The w-acidic group may be a carboxyl, sulphinyl or sulphonyl group. Substitution of any of the functional groups generally causes total loss of excitatory activity, but an exception is found in kainic acid in which the nitrogen atom forms part of a ring. 4. The investigation of a wide variety of compounds revealed neuro- muscular blocking activity among isoxazoles, hydroxylamines, indolealkyl- amines, /?-carbolines, phenazines and phenothiazines. No specific antagonist of the locust glutamate receptor was found, but synaptic blocking agents of moderately high activity are reported. INTRODUCTION The study of arthropod neuromuscular physiology has been impeded by the lack of an antagonist which can be used to block excitatory synaptic transmission by a specific postsynaptic effect.
    [Show full text]
  • Toxicol Rev 2004; 23 (1): 21-31 GHB SYMPOSIUM 1176-2551/04/0001-0021/$31.00/0
    Toxicol Rev 2004; 23 (1): 21-31 GHB SYMPOSIUM 1176-2551/04/0001-0021/$31.00/0 2004 Adis Data Information BV. All rights reserved. γ-Butyrolactone and 1,4-Butanediol Abused Analogues of γ-Hydroxybutyrate Robert B. Palmer1,2 1 Toxicology Associates, Prof LLC, Denver, Colorado, USA 2 Rocky Mountain Poison & Drug Center, Denver, Colorado, USA Contents Abstract ................................................................................................................21 1. Clinical Effects .......................................................................................................23 2. Diagnosis and Management ..........................................................................................25 3. Withdrawal ..........................................................................................................26 4. Conclusion ..........................................................................................................29 Abstract γ-Hydroxybutyrate (GHB) is a GABA-active CNS depressant, commonly used as a drug of abuse. In the early 1990s, the US Drug Enforcement Administration (DEA) warned against the use of GHB and restricted its sale. This diminished availability of GHB caused a shift toward GHB analogues such as γ-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) as precursors and surrogates. Both GBL and 1,4-BD are metabolically converted to GHB. Furthermore, GBL is commonly used as a starting material for chemical conversion to GHB. As such, the clinical presentation and management of GBL and 1,4-BD
    [Show full text]
  • Safety Review of Gamma-Aminobutyric Acid (GABA)
    nutrients Review United States Pharmacopeia (USP) Safety Review of Gamma-Aminobutyric Acid (GABA) Hellen A. Oketch-Rabah 1,*, Emily F. Madden 1, Amy L. Roe 2 and Joseph M. Betz 3 1 U.S. Pharmacopeial Convention, 12601 Twinbrook Parkway, Rockville, MD 20852, USA; [email protected] 2 The Procter & Gamble Company, Cincinnati, OH 45202, USA; [email protected] 3 Office of Dietary Supplements, National Institutes of Health, Bethesda, MD 20892, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-301-230-3249 Abstract: Gamma-amino butyric acid (GABA) is marketed in the U.S. as a dietary supplement. USP conducted a comprehensive safety evaluation of GABA by assessing clinical studies, adverse event information, and toxicology data. Clinical studies investigated the effect of pure GABA as a dietary supplement or as a natural constituent of fermented milk or soy matrices. Data showed no serious adverse events associated with GABA at intakes up to 18 g/d for 4 days and in longer studies at intakes of 120 mg/d for 12 weeks. Some studies showed that GABA was associated with a transient and moderate drop in blood pressure (<10% change). No studies were available on effects of GABA during pregnancy and lactation, and no case reports or spontaneous adverse events associated with GABA were found. Chronic administration of GABA to rats and dogs at doses up to 1 g/kg/day showed no signs of toxicity. Because some studies showed that GABA was associated with decreases Citation: Oketch-Rabah, H.A.; in blood pressure, it is conceivable that concurrent use of GABA with anti-hypertensive medications Madden, E.F.; Roe, A.L.; Betz, J.M.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,040,552 B2 Arnelle Et Al
    US009040552B2 (12) United States Patent (10) Patent No.: US 9,040,552 B2 Arnelle et al. (45) Date of Patent: May 26, 2015 (54) SELECTIVE OPIOID COMPOUNDS Cancer online, retrieved on Jul. 6, 2007. Retrieved from the internet, URL http://www.nlm.nih.gov/medlineplus/cancer.html>.* (71) Applicant: Alkermes, Inc. Cancer online, retrieved on Jul. 6, 2007. Retrieved from the internet, URL: http://en.wikipedia.org.wiki|Cancer.* (72) Inventors: Derrick Arnelle, Arlington, MA (US); Irritable Bowel Syndrome online). Retrieved on Nov. 4, 2014 from Daniel Deaver, Franklin, MA (US); the internet. URL http://digestive.niddk.nih.gov/ddiseases/pubs/ Reginald L. Dean, III, Boxborough, bSt. MA (US); Mark Todtenkopf, Franklin, MA (US) * cited by examiner (73) Assignee: Alkermes, Inc., Waltham, MA (US) Primary Examiner — Shawquia Jackson *) Notice: Subject to anyy disclaimer, the term of this (74) Attorney, Agent, or Firm — Elmore Patent Law Group, patent is extended or adjusted under 35 U.S.C. 154(b) by 97 days. P.C.; Roy P. Issac; Carolyn S. Elmore (21) Appl. No.: 13/693,662 (57) ABSTRACT (22) Filed: Dec. 4, 2012 The present invention relates to compounds of Formula I or II, (65) Prior Publication Data or pharmaceutically acceptable salts, esters, or prodrugs US 2014/OOO5215A1 Jan. 2, 2014 thereof: Related U.S. Application Data (62) Division of application No. 12/371,334, filed on Feb. (I) 13, 2009, now Pat. No. 8,354,534. (60) Provisional application No. 61/028,780, filed on Feb. 14, 2008, provisional application No. 61/087,295, filed on Aug. 8, 2008. (51) Int.
    [Show full text]
  • Internal Aeration and Respiration of Submerged Tomato Hypocotyls Is Enhanced by Ethylene‐Mediated Aerenchyma Formation And
    Internal aeration and respiration of submerged tomato hypocotyls is enhanced by ethylene-mediated aerenchyma formation and hypertrophy Mignolli Francescoa,c, Juan Santiago Todarob and María Laura Vidoza,c,* aInstituto de Botánica del Nordeste (IBONE), UNNE-CONICET, Corrientes, Argentina bFacultad de Medicina, Universidad Nacional del Nordeste (UNNE), Corrientes, Argentina cFacultad de Ciencias Agrarias, Universidad Nacional del Nordeste (UNNE), Corrientes, Argentina Correspondence *Corresponding author, e-mail: [email protected] With the impending threat that climate change is imposing on all terrestrial ecosystems, plants’ ability to adjust to changing environments is, more than ever, a very desirable trait. Tomato (Solanum lycopersicum L.) plants display a number of responses that allow them to survive under different abiotic stresses such as flooding. We focused on understanding the mechanism that facilitates oxygen diffusion to submerged tissues and the impact it has on sustaining respiration levels. We observed that, as flooding stress progresses, stems increase their diameter and internal porosity. Ethylene triggers stem hypertrophy by inducing cell wall loosening genes, and aerenchyma formation seems to involve programmed cell death mediated by oxygen peroxide. We finally assessed whether these changes in stem morphology and anatomy are indeed effective to restore oxygen levels in submerged organs. We found that aerenchyma formation and hypertrophy not only increase oxygen diffusion towards the base of the plant but also result in an augmented respiration rate. We consider that this response is crucial to maintain adventitious root development under such conditions and, therefore, making it possible for the plant to survive when the original roots die. Introduction This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record.
    [Show full text]
  • 1 Production and Actions of Hydrogen Sulfide, A
    JPET Fast Forward. Published on February 26, 2009 as DOI: 10.1124/jpet.108.149963 JPET FastThis Forward.article has not Published been copyedited on and February formatted. The26, final 2009 version as DOI:10.1124/jpet.108.149963may differ from this version. JPET #149963 PRODUCTION AND ACTIONS OF HYDROGEN SULFIDE, A NOVEL GASEOUS BIOACTIVE SUBSTANCE, IN THE KIDNEYS Downloaded from Min Xia, Li Chen, Rachel W. Muh, Pin-Lan Li, Ningjun Li Department of Pharmacology & Toxicology, jpet.aspetjournals.org Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298 (M.X, L.C., R.W.M., P.L.L., N.L.) at ASPET Journals on October 2, 2021 1 Copyright 2009 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on February 26, 2009 as DOI: 10.1124/jpet.108.149963 This article has not been copyedited and formatted. The final version may differ from this version. JPET #149963 Running Title: Hydrogen sulfide and renal function Send Correspondence to: Dr. Ningjun Li Department of Pharmacology & Toxicology Medical College of Virginia Virginia Commonwealth University PO Box 980613 Richmond, VA 23298 Downloaded from Phone: 804 828-4562 Fax: 804 828-4794 E-mail: [email protected] jpet.aspetjournals.org Number of text pages: 14 Number of tables: 2 Number of figures: 5 Number of references: 40 Words in the Abstract: 246 at ASPET Journals on October 2, 2021 Introduction: 325 Discussion: 1418 List of nonstandard abbreviations: H2S, hydrogen sulfide; L-Cys, L-cysteine; CBS, cystathionine β-synthetase; CGL, cystathionine γ-lyase; AOAA, aminooxyacetic acid; PPG, propargylglycine; GFR, glomerular filtration rate; U·V, urinary volume; UNa·V, urinary sodium; UK·V, urinary potassium; FF, fractional filtration; FENa, fractional excretion of sodium; FEK, fractional excretion of potassium; NHE, Na+/H+ exchanger; NKCC, Na+/K+/2Cl- cotransporter; NCC, Na+/Cl- cotransporter; ENaC, epithelial Na+ channel; NKA, Na+/K+-ATPase; CA Carbonic Anhydrase.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Aminooxyacetic Acid (hydrochloride) Item No. 28298 CAS Registry No.: 2921-14-4 Formal Name: 2-(aminooxy)-acetic acid, hemihydrochloride Synonym: Aminooxyacetate O MF: C2H5NO3 • 1/2HCl O FW: 109.3 HO NH2 Purity: ≥95% • 1/2HCl Supplied as: A crystalline solid Storage: -20°C Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Aminooxyacetic acid (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the aminooxyacetic acid (hydrochloride) in the solvent of choice, which should be purged with an inert gas. Aminooxyacetic acid (hydrochloride) is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of aminooxyacetic acid (hydrochloride) in these solvents is approximately 5 and 2 mg/ml, respectively. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of aminooxyacetic acid (hydrochloride) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of aminooxyacetic acid (hydrochloride) in PBS, pH 7.2, is approximately 5 mg/ml. We do not recommend storing the aqueous solution for more than one day. Description Aminooxyacetic acid is a GABA transaminase (GABA-T) inhibitor (Ki = 9.16 μM) that induces GABA accumulation in the brain.1 It also inhibits cystathionine β synthase (CBS) and cystathionine γ lyase 2 (CSE; IC50s = 8.5 and 1.1 μM, respectively).
    [Show full text]